1 / 42

Gout Update 2014

Gout Update 2014. Bernadette C. Siaton, MD Assistant Professor of Medicine University of Maryland School of Medicine Division of Rheumatology and Clinical Immunology 1 February 2014. Disclosures . none. Objectives. Review FDA-approved dosing guidelines for colchicine (Colcrys)

trula
Download Presentation

Gout Update 2014

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Gout Update 2014 Bernadette C. Siaton, MD Assistant Professor of Medicine University of Maryland School of Medicine Division of Rheumatology and Clinical Immunology 1 February 2014

  2. Disclosures • none

  3. Objectives Review FDA-approved dosing guidelines for colchicine (Colcrys) Evaluate the safety of allopurinol in the setting of chronic kidney disease Compare efficacy of available xanthine oxidase inhibitors (allopurinol vs. febuxostat) in treatment of gout Review the EULAR and ACR management guidelines for gout

  4. 5 Gout Commandments Hyperuricemia ≠ Gout Goal sUA < 6 Use prophylaxis for at least 3 months after initiating gout therapy Do not stop gout medication unless patient is showing evidence of drug toxicity or adverse reaction Ask your friendly rheumatologist for help!

  5. Gout Management –the Score Card • 52.8% of PCP provided optimal medication treatment for acute attack • 3.4% of PCPs would appropriately treat inter-critical gout in the setting of CKD • 16.7% provided optimal care for chronic tophaceous gout • Primary Care and ER Physicians are first line for acute gouty attacks • Education needed to optimize outcomes and limit toxicity • Need for formal guidelines for rheumatology referral Harrold LR, et al. Rheumatology, 2013.

  6. Healthcare Utilization • Rheumatologists vs. Non-rheumatologists • ER visits (Nationwide Sample of 20% of ERs) • 0.2% of all ER visits • $166 million in ED charges alone in 2008 Panush RS, et al. J Clin Rheumatol. 1995 Apr; 1(2):74-80 Garg R, et al. Semin Arthritis Rheum. 2011 Jun;40(6):501-11.

  7. Gout Management Approach INITIATE (acute flare) • Treat acute flare rapidly with anti-inflammatory agent • Initiate urate-lowering therapy to achieve sUA <6 • Use concomitant anti-inflammatory prophylaxis for up to 6 mo to prevent mobilization flares RESOLVE (urate-lowering therapy) • Continue urate lowering therapy to control flares and avoid crystal deposition • Prophylaxis use for at least 3-6 months until sUA normalizes MAINTAIN (treatment to control sUA) 7

  8. Myth #1 • Acute gout flares are treated with 1 tablet of colchicine hourly until the patient develops diarrhea or gets better.

  9. AGREE study: Acute Gout Flare Receiving ColchicinEEvaluation High vs. Low Dose Colchicine for Gout Flare Randomized, double-blind, placebo-controlled study Low dose colchicine (1.8mg total over 1 h) High dose colchicine (4.8mg total over 6 h) Primary end point: >50% pain reduction in 24 hours without rescue medication 184 patients intent-to-treat analysis Terkeltaub, RA., et al. Arthritis Rheum 2010.

  10. AGREE study: Acute Gout Flare Receiving ColchicinEEvaluation Terkeltaub, RA., et al. Arthritis Rheum 2010.

  11. Improvement in pain @ 24 hours High-dose Low-dose placebo Terkeltaub, RA., et al. Arthritis Rheum 2010.

  12. Take home points • Low-dose colchicine had similar efficacy to high-dose colchicine with lower adverse effect profile • Colchicine now has FDA-approved dosing based on creatinine clearance • CrCl 30-80 ml/min = 0.6mg daily • CrCl <30 ml/min = 0.3mg daily • HD = 0.6mg twice weekly (not dialyzable) Terkeltaub, RA., et al. Arthritis Rheum 2010.

  13. Myth #2 You cannot use allopurinol in patients with renal insufficiency

  14. Allopurinol and Renal Insufficiency • 1984 Hande, et al published “Severe allopurinol toxicity: Description and guidelines for prevention in patients with renal insufficiency” • “Avoidance of allopurinol or use of reduced doses in patients with renal insufficiency according to proposed guidelines should be adequate to inhibit uric acid production in most patients and may reduce the incidence of life-threatening allopurinol toxicity.” Hande KR, et al. Am J Med, 1984.

  15. Maintenance Doses of Allopurinol for Adults based on CrCl Stage 1 renal damage with normal GFR (GFR > 90 ml/min) Stage 2 Mild CKD (GFR = 60-89 ml/min) Stage 3 Modererate CKD (GFR = 30-59 ml/min) Stage 4 Severe CKD (GFR = 15-29 ml/min) Stage 5 End Stage CKD (GFR <15 ml/min) Hande KR, et al. Am J Med, 1984.

  16. What did doctors take home? Guidelines made in order to prevent allopurinol hypersensitivity Allopurinol should not be used in renal insufficiency Hande KR, et al. Am J Med, 1984.

  17. Pathophysiology XO XO hypoxanthine xanthine urate XO=xanthine oxidase Allopurinol and febuxostat inhibit xanthine oxidase and block uric acid formation 17 Markel A. IMAJ, 2005.

  18. Oxypurinol Allopurinol Hypersensitivity Syndrome Xanthine Oxidase oxypurinol Toxic Epidermal Necrolysis allopurinol Stevens-Johnson Syndrome Oxypurinol, allopurinol metabolite, cleared by kidney and accumulates in patients with renal failure Oxypurinol inhibits xanthine oxidase Increased oxypurinol related to risk of allopurinol hypersensitivity syndrome

  19. Allopurinol Hypersensitivity Syndrome • 2% of all allopurinol users develop cutaneous rash • Frequency of hypersensitivity 1 in 260 • DRESS syndrome • Drug Reaction, Eosinophilia, Systemic Symptoms • 20% mortality rate • Life threatening toxicity: vasculitis, rash, eosinophilia, hepatitis, progressive renal failure • Treatment: early recognition, withdrawal of drug, supportive care • Steroids, N-acetyl-cysteine, dialysis prn Markel A. IMAJ, 2005. Terkeltaub RA, in Primer on the Rheumatic Disease, 13th ed. 2008.

  20. Relationship between recommended allopurinol dose and sUA < 6 • Dose reduction of allopurinol in patients with renal insufficiency may lead to under-treatment and persistent hyperuricemia • Dalbeth, et al. created allopurinol calculator • Performed retrospective chart review of 250 patients with ACR criteria for gout • Divided into 4 groups: • no allopurinol • lower than recommended allopurinol dose • recommended allopurinol dose • higher than recommended allopurinol dose Dalbeth N, et al. J Rheum, 2006.

  21. Results • 227/250 (90.8%) were taking allopurinol • Mean allopurinol dose was 214mg/day • 9.7% took lower than recommended doses • 70.9% took recommended doses • 19.4% took higher than recommended doses • 4/250 (1.6%) developed hypersensitivity • All took recommended doses Dalbeth N, et al. J Rheum, 2006.

  22. Is recommended dose of allopurinol enough? 19% (recommended) vs 38% (higher than recommended) reached sUA <6, p <0.01 Dalbeth N, et al. J Rheum, 2006.

  23. Is recommended dose of allopurinol enough? • Limitations: • Retrospective study • Homogenous population (Maori/Pacific Islanders) • Cannot judge medication compliance • Conclusions: • Allopurinol dosing according to published guidelines has NOT led to adequate control of hyperuricemia Dalbeth N, et al. J Rheum, 2006.

  24. Myth #3 The maximum dose of allopurinol in patients with renal insufficiency should not exceed 300mg

  25. Allopurinol dosing algorithm Stage 1 renal damage with normal GFR (GFR > 90 ml/min) Stage 2 Mild CKD (GFR = 60-89 ml/min) Stage 3 Modererate CKD (GFR = 30-59 ml/min) Stage 4 Severe CKD (GFR = 15-29 ml/min) Stage 5 End Stage CKD (GFR <15 ml/min) Hande KR, et al. Am J Med, 1984.

  26. Allopurinol Use in Renal Insufficiency • Objective: • Determine the safety and efficacy of increasing allopurinol dose above the proposed guidelines for patients with gout • Prospective study of patients on allopurinol ≥ 1 month • 81.9% European, 14.4% Maori or Pacific Island Descent • Saw patients monthly and titrated allopurinol until sUA <6 for 3 months then q3 months Stamp LK, et al. Arthritis Rheum 2011.

  27. Allopurinol Use in Renal Insufficiency Stamp LK, et al. Arthritis Rheum 2011.

  28. Allopurinol Use in Renal Insufficiency • Mean baseline dosage • 221.4mg (range 100-400, median 200) • Mean dose for pts who completed study • 335.7mg (range 0-600, median 350) • Mean dose for pts who achieved sUA <6 • 359.7mg (range 150-600, median 450) Stamp LK, et al. Arthritis Rheum 2011.

  29. Conclusions Doses above recommended dose are effective for lowering sUA with few adverse events Patients with renal impairment tolerated allopurinol doses higher than CrCl-based doses and achieved sUA <6 Monitor sUA regularly and treat-to-target sUA <6 Limitations of study: self-selected patients who were already on allopurinol → minimize incidence of toxicity Stamp LK, et al. Arthritis Rheum 2011.

  30. Allopurinol vs. Febuxostat

  31. Allopurinol vs. Febuxostat • Phase III, randomized, double-blind, allopurinol and placebo-controlled parallel-group trial • Primary end point: proportion of subjects with the last 3 monthly sUA <6 regardless of whether or not subject completed the study • Randomized 2:2:1:2:1 • febuxostat 80mg: 120mg: 240mg: allopurinol: placebo Schumacher HR, et al. Arthritis Rheum 2008.

  32. Proportion of subjects with last 3 monthly sUA <6 Schumacher HR, et al. Arthritis Rheum 2008.

  33. Schumacher HR, et al. Arthritis Rheum 2008.

  34. Adverse Events *Statistically significant versus febuxostat 240mg p ≤ 0.05 **Statistically significant versus allopurinol p ≤ 0.05 ***Statistically significant versus placebo p ≤ 0.05 Schumacher HR, et al. Arthritis Rheum 2008.

  35. Discussion Febuxostat effectively reduced sUA <6 Allopurinol dose fixed instead of titrated Patients with impaired renal function did not achieve sUA <6 with recommended allopurinol dose of 100mg AE profile similar across treatment groups except for diarrhea and dizziness higher in febuxostat 240mg group Schumacher HR, et al. Arthritis Rheum 2008.

  36. Official treatment guidelines

  37. Treatment: Summary of EULAR Recommendations • Therapeutic goal of urate-lowering therapy is sUA <6.0 mg/dL • Urate lowering therapy indications: • Recurrent gout attacks • Tophi and/or radiographic changes on initial presentation • Address associated risk factors and comorbidities – tailor to the individual 37 Zhang W, et al. Ann Rheum Dis. 2006; 65: 1312-1324.

  38. 2012 ACR Management Guidelines • Lifestyle Modification for all patients with gout • Xanthine Oxidase Inhibitor (XOI) first-line urate-lowering pharmacologic therapy • Target sUA <6 at minimum, sUA <5 better • Starting dose of allopurinol should be 100mg, less in CKD with titration above 300mg prn if needed (even in CKD) • Continue prophylaxis for 3 (no tophi) – 6 months (tophi) after achieving target sUA Khanna D, et al. Arthritis Care Res . 2012 Oct;64(10):1431-46

  39. 2012 ACR Management Guidelines • Consider HLA screening for HLA-B*5801 in certain populations considered high risk for allopurinol hypersensitivity syndrome • Koreans with stage 3 CKD or worse • Han Chinese • Thai descent • Combination oral ULT with 1 XOI agent and 1 uricosuric agent is appropriate when sUA not at target by XOI alone • Pegloticase appropriate for severe refractory disease or intolerance of standard regimens Khanna D, et al. Arthritis Care Res. 2012 Oct;64(10):1431-46

  40. 2012 ACR Management Guidelines for Acute Gouty Arthritis • The choice of pharmacologic agent depends on severity of the attack • Monotherapy for mild/moderate attack • Combination therapy for severe attack or those refractory to monotherapy • Acceptable combination therapy approaches include • Colchicine and NSAIDS • Oral steroids and colchicine • Intra-articular steroids with all other modalities • Continue current therapy during flare • Patient education on signs of flare for self treatment Kanna D, et al. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1447-61

  41. Take Home Points • Goal sUA < 6, and use concurrent prophylaxis • Colchicine has FDA-approved dosing guidelines for chronic kidney disease • Allopurinol doses above recommended CrCl-based dose is effective with minimal adverse effect • Febuxostat is an excellent alternative for patients with renal insufficiency • Other treatment alternatives exist, please refer to your friendly rheumatologist for difficult cases

  42. QUESTIONS? bsiaton@medicine.umaryland.edu

More Related